Clinical Trials Center

CTC volunteer receiving injection from uniformed doctor

The Clinical Trials Center (CTC) was established in early 1992 to support Army and Navy investigators in their mission to develop new vaccines, drugs, and diagnostic systems to meet high-priority Department of Defense and national security needs. As part of WRAIR, the CTC is fully integrated within a network designed to bring products to market with an average of 5-10 new studies each year.

Since its inception, the CTC has conducted over 150 clinical trials of drugs and vaccines for a variety of infectious diseases, including Ebola, Japanese encephalitis, Zika, HIV and many others. 

Learn more here about holding a clinical trial at WRAIR or WRAIR's network of affiliated laboratories around the world or contact us.

Recruiting Studies

Severe acute respiratory syndrome coronavirus (SARS-CoV-2), which causes the COVID-19 disease, is a new virus that is spreading from person-to-person throughout the world. In most people, it causes mild to moderate symptoms, but in others, this virus can cause pneumonia (an inflammation of the lungs), which can be serious and life threatening, particularly among the elderly, people with weak immune systems, or people with underlying health conditions. To date, there are no FDA-licensed COVID-19 vaccines, however some vaccines have been given Emergency Use Authorization.
This study seeks to demonstrate that three different batches of the live-attenuated, chikungunya vaccine have comparable safety profiles and lead to similar immune responses among vaccine recipients 18 to 45 years of age.
The FMP013/FMP014 vaccines have been designed to prevent malaria caused by Plasmodium falciparum. This is the first time these vaccine will be tested in humans. Ultimately, this trial will help determine if these experimental malaria vaccines are safe and tolerable and helps your body to make the antibodies that protect against malaria.
This specimen collection study is seeking to enroll volunteers from the community to identify a group of individuals for a phase 1 clinical trial that’s currently in development by WRAIR and for other SARS-CoV-2/COVID-19 related trials.